Hepatocellular Carcinoma

- Localized
  - No Prior Therapy
    - 1st Line
      - IRB #20929
        Phase II study of TSR-022 (COBOLIMAB) in combination with TSR-042 (DOSTARIMAB) for the treatment of advanced hepatocellular carcinoma
    - 2nd Line
  - Prior Therapy
    - 1st or 2nd Line
    - 2nd Line or more

Cholangiocarcinoma

- 1st Line
  - IRB #20357 [NCI CIRB]
    Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
  - IRB #16033
    Phase II study of induction systemic mFOLFOXIRI followed by hepatic arterial infusion of Floxuridine and Dexamethasone given concurrently with systemic mFOLFOXIRI as a first-line therapy in patients with unresectable liver-dominant intrahepatic cholangiocarcinoma

- 1st or 2nd Line
  - No Trials Currently Available

- 2nd Line or more
  - IRB #24798
    A Phase 1/1b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of KIN-3248 in Participants with Advanced Tumors Harboring FGFR2 and FGFR3 Gene Alterations

CROSS-DISEASE TRIALS:

- IRB #19992
  - EAY131 (MATCH)
  
https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result
GI Hepatobiliary

IRB# 23005
EA2197, Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial

https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result